These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 3686465

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985].
    Therapie; 1986; 41(5):323-84. PubMed ID: 3810518
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
    Pham E, Ventre JJ, Saddier P, Descotes J, Evreux JC.
    Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Measuring adverse drug reactions in a postmarketing surveillance system.
    Fisher S, Bryant SG, Kluge RM.
    Psychopharmacol Bull; 1986 May; 22(1):272-7. PubMed ID: 3726073
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R, Hottinger S.
    Pharm Acta Helv; 1988 May; 63(1):2-12. PubMed ID: 3283774
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adverse drug reactions.
    Turner P.
    Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
    [No Abstract] [Full Text] [Related]

  • 12. [Drug surveillance as seen by the general practitioner. Apropos of a survey of 4175 physicians].
    Begaud B, Haramburu F, Péré JC, Delmas N, Lorson B, Albin H.
    Therapie; 1984 May; 39(5):453-7. PubMed ID: 6506000
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Necessity and difficulties of quantitative drug monitoring].
    Lagier G, Dally S, Vincens M, Castot A.
    Therapie; 1983 May; 38(3):319-23. PubMed ID: 6612668
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Chemical surveillance in the industrial environment].
    Conso F.
    Rev Prat; 1987 Apr 21; 37(23):1321-5. PubMed ID: 3602879
    [No Abstract] [Full Text] [Related]

  • 17. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
    Lagier G, Vincens M, Castot A.
    Therapie; 1983 Apr 21; 38(3):303-18. PubMed ID: 6612667
    [No Abstract] [Full Text] [Related]

  • 18. Critical reflection on the collection and evaluation of adverse drug reaction data.
    Venulet J.
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr 21; 23 Suppl 1():S48-53. PubMed ID: 3842691
    [No Abstract] [Full Text] [Related]

  • 19. [Comparative organization of drug monitoring in France and 7 European countries].
    Vaissere J, de Cremiers F, Auriche M, Juillet Y.
    Therapie; 1986 Apr 21; 41(5):369-74. PubMed ID: 3810527
    [No Abstract] [Full Text] [Related]

  • 20. [Drug monitoring].
    Royer RJ.
    Bull Soc Ophtalmol Fr; 1985 Nov 21; Spec No():11-30. PubMed ID: 4064240
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.